Int'l App. No.: PCT/US99/26746 Int'l Filing Date: 12 November 1999

REMARKS

The above-identified application is being entered into the National Phase from PCT application no. PCT/US99/26746.

Applicants have amended the claims to put them in conformity with U.S. practice.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

No new matter has been introduced.

Respectfully submitted,

Yariy P. Stercho, Ph.D. Attorney for Applicants Registration No. 33,797

SMITHKLINE BEECHAM CORPORATION Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Phone (610) 270-5018 Facsimile (610) 270-5073 n\yps\response\P32185\preamend Int'l App. No.: PCT/US99/26746 Int'l Filing Date: 12 November 1999

"VERSION WITH MARKING TO SHOW CHANGES MADE"

In the specification:

An abstract has been added.

In the claims:

- 3. (Amended) A method according to [claim 1 or] claim 2, wherein the Threshold Plasma Concentration is within the range of from about 50 to about 120ng/mL or about 60 to about 120ng/mL or about 90 to about 110ng/mL or about 95 to about 105ng/mL.
- 4. (Amended) A method according to [any one of] claim[s] 1 [to 3], wherein a minimum value of the Threshold Plasma Concentration (or the Minimum Threshold Plasma Concentration) of the insulin sensitiser is its SC50 concentration.
- 5. (Amended) A method according to [any one of] claim [1 to] 4, wherein a Preferred Threshold Plasma Concentration for the insulin sensitiser is twice the SC50 concentration.
- 6. (Amended) A method according to [any one of] claim 1 [to 5], wherein the plasma concentration of the insulin sensitiser remains substantially within the range from the Minimum Threshold Plasma Concentration to a level at or above the Preferred Threshold Plasma Concentration.
- 8. (Amended) A method according to [any one of] claim[s 4 to 6] 7, wherein the insulin sensitiser is Compound (I) and the SC50 is within the range of 40 to 65 ng/mL.
- 10. (Amended) A method according to [any one of] claim[s 6 to 9] 7 wherein the insulin sensitiser is Compound (I) and the Preferred Threshold Plasma Concentration is in the range of about 80 to about 130 ng/mL or about 82.2 to about 123.4ng/mL.
- 15. (Amended A method according to any one of claims 1 to 6, wherein the insulin sensitiser is

Int'l App. No.: PCT/US99/26746 Int'l Filing Date: 12 November 1999

selected from the group consisting of 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (or troglitazone), 5-[4-[(1-methylcyclohexyl)methoxy]benzyl] thiazolidine-2,4-dione (or ciglitazone), 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone) [or] and 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl)thiazolidine-2,4-dione (or englitazone).

- 19. (Amended) A modified release composition according to claim [1] 18 being a delayed, pulsed or sustained release composition.
- 20. (Amended) A composition according to [ny one of] claim 16 [to 19], adapted to provide a method of treatment according to [any one] of claim[s] 1 [to 15].